MPATHY BIO

We pioneer advanced diagnostics, providing comprehensive solutions from sample to results.

Who we are

About Us

MPathyBio Inc. ^TM is a leader in advanced diagnostics. Our team includes experts like Dr. Christopher Nelson, Dr. Galina Zybina, Dr. Kristina Clemens, Dr. Shilpa Bandekar, Akshay Jain, and Arun Singh. Founded in 2024, we leverage extensive experience in bioinformatics, and wet-lab development of diagnostics.

We are dedicated to improving diagnostic accuracy with state-of-the-art blood test products. Our mission is to enhance patient care through strong collaborations, as a trusted partner for Biotech and Pharma drug development. Reach out to discuss how we can support your needs.

Learn More

Schedule an appointment

Schedule your appointment

Services

What We Do

At MPathyBio ^TM, we provide advanced biofluid analysis and diagnostic services tailored to your needs. Our methods, built on years developing clinical-grade diagnostics, ensure precise and reliable results.

Advanced Liver Function Testing

Our liver function tests provide accurate data and reduce false positives, ensuring real tissue toxicity detection for better drug safety data confidence.

Biomarker Discovery

Our reliable machine learning methods identify robust biomarkers of drug safety, efficacy and disease state. Contact us if you'd like to discus biomarker development for your indication.

On-Demand Bioinformatics Deep-Dives

Need to better understand adverse events or trouble shoot diagnostic assay performance? We are an attentive partner. Follow the contact us link to discuss how we can help in a hurry.

Testimonials

What our partners say about the impact of our diagnostic services.

Drug-induced liver injury (DILI) is a common finding in preclinical and clinical studies. The FDA scrutinizes data for any sign of DILI. False positive signals from AST/ALT can trigger significant program delays to investigate mechanism of action and confirm drug safety. I want a liver toxicity test with higher sensitivity and specificity.

Jay Stallons PhD DBAT

It’s hard to separate true drug safety signals from false ones with current tests. This harms clinical safety trial power. Liver toxicity screening is stuck in the ‘90s with very low data input. The current LFT is insufficent.

Julia Warren MD PhD

MPathy Bio’s focus on reduced false positives in toxicity biomarkers is well aligned with the needs of our cohort studies on the extension of health and lifespan in dogs. Having high sensitivity and specificity tests for therapy-induced liver toxicity would be superior to the relatively simplistic status quo that can be inaccurate due to a transient or benign biological state in the dog, such as dehydration.